BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 24481317)

  • 1. Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients.
    Nakamura R; Inage Y; Tobita R; Mori K; Numata T; Yanai H; Endo T; Ohtani H; Satoh H; Yuzawa K; Koizumi M; Ueki H
    J Thorac Oncol; 2014 Sep; 9(9):1340-4. PubMed ID: 24481317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
    Argiris A; Hensing T; Yeldandi A; Patel S; Raji A; Sturgis C; Masters G; Gooding W; Pins M; Kolesar J
    J Thorac Oncol; 2006 Jan; 1(1):52-60. PubMed ID: 17409827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
    Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
    Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
    Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
    Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C; Liu M; Zhou C; Zhang J; Ouyang M; Zhong N; Xu J
    Int J Cancer; 2009 Nov; 125(10):2393-9. PubMed ID: 19530244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Sunaga N; Sato K; Takise A; Otani Y; Tanaka S; Suga T; Saito R; Ishizuka T; Dobashi K; Minna JD; Nakajima T; Mori M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6816-22. PubMed ID: 16203769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
    Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
    Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
    Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.
    Yatabe Y; Kerr KM; Utomo A; Rajadurai P; Tran VK; Du X; Chou TY; Enriquez ML; Lee GK; Iqbal J; Shuangshoti S; Chung JH; Hagiwara K; Liang Z; Normanno N; Park K; Toyooka S; Tsai CM; Waring P; Zhang L; McCormack R; Ratcliffe M; Itoh Y; Sugeno M; Mok T
    J Thorac Oncol; 2015 Mar; 10(3):438-45. PubMed ID: 25376513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
    Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
    J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
    Molina-Vila MA; Bertran-Alamillo J; Reguart N; Taron M; Castellà E; Llatjós M; Costa C; Mayo C; Pradas A; Queralt C; Botia M; Pérez-Cano M; Carrasco E; Tomàs M; Mate JL; Moran T; Rosell R
    J Thorac Oncol; 2008 Nov; 3(11):1224-35. PubMed ID: 18978556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
    McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
    Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
    Takano T; Ohe Y; Sakamoto H; Tsuta K; Matsuno Y; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Shibata T; Sakiyama T; Yoshida T; Tamura T
    J Clin Oncol; 2005 Oct; 23(28):6829-37. PubMed ID: 15998907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.